Combined preparation mixed administration equipment for blue light induced ocular surface cell inflammation

Abstract

The utility model discloses combined preparation mixed administration equipment for blue light induced ocular surface cell inflammation, which relates to the technical field of reagent preparation and administration equipment, and comprises a human conjunctiva (IOBA-NHC) and cornea (HCE) epithelial cell line cell incubator, and the interior of the incubator is a light-proof environment; a blue light-emitting diode is arranged in the incubator to provide a rich blue environment, a clamping rod is arranged, and two sets of identical equipment are arranged on the left side and the right side of a partition plate, so that QCT and RES reagents with initial concentrations are arranged in the test equipment on the left side of the partition plate when a drug test is carried out through mixed drug delivery equipment; according to experimental data, the concentration of the QCT and the RES can be continuously adjusted by the mixed administration equipment for preparing the reagent in a combined manner, quantitative proportioning is performed, benzalkonium chloride (0.005%) is arranged in the test equipment on the right side of the partition plate and serves as blank control, and multiple repeated experiments are performed to collect data so as to find the optimal concentration interval of the QCT and RES combined preparation for treating blue light oxidative damage ocular surface cells. And the effect of improving the placement stability between the equipment and the whole equipment is achieved.

Description

Technical Field

[0001] The utility model relates to the technical field of reagent dosing equipment, in particular to a combined preparation mixed dosing equipment for blue light-induced ocular surface cell inflammation. Background Art

[0002] Blue light (BL) is a pathogenic factor of ocular surface inflammation and can cause severe ocular phototoxicity. The research on the correlation of BL with ocular surface inflammation is still relatively scarce. Ocular surface structures such as the cornea, conjunctiva and tear film are the first barrier between light and the entire visual system. It is still unclear whether there are effective therapeutic drugs for ocular surface inflammation caused by blue light-induced oxidative stress in ocular surface cells. This experiment uses an automatic mixing and proportioning dosing device to find the optimal concentration range of QCT and RES mixed preparations to find effective treatment effects on patients' eyes.

[0003] However, multiple repeated experiments are required when preparing QCT and RES combined preparations and administering them in combination. Although manual operation can perform better mixing operations on QCT and RES reagents, the mixing of reagents is only observed and operated by the naked eye of the experimenter. The experimental efficiency is low and it is difficult to control system errors, which reduces the accuracy of the optimal concentration range of the QCT and RES combined preparation.

[0004] Therefore, in view of this, the existing structural deficiencies are studied and improved, and a combined preparation mixed delivery device for blue light-induced ocular surface cell inflammation is proposed. Utility Model Content

[0005] The purpose of the utility model is to provide a combined preparation mixed administration device for blue light-induced ocular surface cell inflammation, so as to solve the problems of low experimental efficiency and difficulty in controlling system errors proposed in the above-mentioned background technology, and the problem of reducing the accuracy of the optimal concentration range of QCT and RES combined preparations.

[0006] To achieve the above-mentioned purpose, the utility model provides the following technical solutions: a combined preparation mixed drug delivery device for blue light-induced ocular surface cell inflammation, comprising a device as a whole, a partition fixedly connected to the inner wall of the device as a whole, a pull-out plate slidably connected to the inner wall of the device as a whole, an incubator engaged with the inner wall of the device as a whole is placed on the outer wall of the pull-out plate, a blue light-emitting diode is arranged inside the incubator, a cytotoxicity measuring device located below it is placed on the inner wall of the device as a whole, a GSH and ROS measuring device located below the cytotoxicity measuring device is placed on the inner wall of the device as a whole, the detection devices of the cytotoxicity measuring device and the GSH and ROS measuring device are all connected to the incubator, and a QCT and RES combined preparation mixed drug delivery device located above the incubator and embedded with the incubator is arranged inside the device as a whole. The side wall of the entire device is fixedly connected with a handle, the back of the incubator is fixedly connected with a connecting block, the outer wall of the connecting block is fixedly connected with a fixing block, the inner wall of the entire device is fixedly connected with a positioning block located on one side of the fixing block, the outer wall of the positioning block is slidably connected with a clamping rod, the outer wall of the clamping rod is fixedly connected with a telescopic rod slidably connected to the outer wall of the positioning block, the outer wall of the telescopic rod is sleeved with a spring fixedly connected to the outer wall of the positioning block, one end of the spring is fixedly connected with a pulling block fixedly connected to one end of the telescopic rod, and a clamping groove is provided at the connection position between the outer wall of the fixed block and the clamping rod.

[0007] Furthermore, the incubator, QCT and RES combined preparation mixed dosing device, cytotoxicity determination device and GSH and ROS determination device are each provided with two groups, and the positions of the two groups of incubators, QCT and RES combined preparation mixed dosing device, cytotoxicity determination device and GSH and ROS determination device are distributed symmetrically with respect to the central axis of the partition.

[0008] Furthermore, the blue light emitting diodes are provided in four groups, and the positions of the four groups of blue light emitting diodes are distributed around the entire device.

[0009] Furthermore, the pull-out plates and the connecting blocks are arranged in a one-to-one correspondence.

[0010] Furthermore, the outer wall contours of the positioning block and the clamping rod are in an arc shape.

[0011] Furthermore, the inner wall contour of the clamping slot is larger than the outer wall contour of the clamping rod.

[0012] Compared with the prior art, the beneficial effects of the utility model are:

[0013] The utility model is provided with two groups of completely identical incubators, QCT and RES combined preparation mixed administration equipment, cytotoxicity determination equipment, GSH and ROS determination equipment and a card rod. When a drug test is conducted through the mixed administration equipment, the initial concentration of QCT and RES reagents can be applied in the test equipment on the left side of the partition. According to the experimental data, the combined preparation mixed administration equipment will continuously adjust the concentration of QCT and RES, perform quantitative proportioning, and apply benzalkonium chloride as a blank control in the test equipment on the right side of the partition to find the maximum no-effect dose and the minimum effect dose, and perform repeated experiments to collect data to find the optimal concentration range of QCT and RES combined preparation for treating blue light oxidative damage to ocular surface cells. At the same time, in order to improve the stability of the device placed in the overall device, the fixed block and the card rod can be fitted together through the connection of the connecting block, and when the connection part of the card rod and the fixed block is in an arc shape, the telescopic rod and the spring are squeezed until the card rod slides into the inner wall of the card slot, which plays a role in improving the placement stability between the device and the overall device. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 It is a schematic diagram of the overall three-dimensional structure of the equipment;

[0015] Figure 2 This is a schematic diagram of the blue light emitting diode position distribution structure;

[0016] Figure 3 It is a schematic diagram of the connection structure between the fixed block and the clamping rod;

[0017] Figure 4 This is a schematic diagram of the pull-out plate structure.

[0018] In the figure: 1. The whole equipment; 2. Partition; 3. Pull-out plate; 4. Incubator; 5. Blue light-emitting diode; 6. Cytotoxicity determination equipment; 7. GSH and ROS determination equipment; 8. Handle; 9. Connecting block; 10. Fixing block; 11. Positioning block; 12. Clamping rod; 13. Telescopic rod; 14. Spring; 15. Pull block; 16. Clamping slot; 17. QCT and RES combined preparation mixed drug delivery equipment. DETAILED DESCRIPTION

[0019] The following will be combined with the drawings in the embodiments of the utility model to clearly and completely describe the technical solutions in the embodiments of the utility model. Obviously, the described embodiments are only part of the embodiments of the utility model, not all of the embodiments. Based on the embodiments in the utility model, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the utility model.

[0020] Example: Figure 1-Figure 4As shown, a combined preparation mixed drug delivery device for blue light-induced ocular surface cell inflammation includes a device as a whole 1, a partition 2 is fixedly connected to the inner wall of the device as a whole 1, a pull-out plate 3 is slidably connected to the inner wall of the device as a whole 1, an incubator 4 that is snap-connected to the inner wall of the device as a whole 1 is placed on the outer wall of the pull-out plate 3, a blue light-emitting diode 5 is arranged inside the incubator 4, a cytotoxicity measuring device 6 is placed below the inner wall of the device as a whole 1, a GSH and ROS measuring device 7 is placed below the cytotoxicity measuring device 6 on the inner wall of the device as a whole 1, the detection devices of the cytotoxicity measuring device 6 and the GSH and ROS measuring device 7 are both connected to the incubator 4, and a blue light-emitting diode 5 is arranged inside the incubator 4 above the incubator 4. An incubator-embedded QCT and RES combined preparation mixed drug delivery device 17, the side wall of the device as a whole 1 is fixedly connected with a handle 8, the back of the incubator 4 is fixedly connected with a connecting block 9, the outer wall of the connecting block 9 is fixedly connected with a fixing block 10, the inner wall of the device as a whole 1 is fixedly connected with a positioning block 11 located on one side of the fixing block 10, the outer wall of the positioning block 11 is slidably connected with a clamping rod 12, the outer wall of the clamping rod 12 is fixedly connected with a telescopic rod 13 slidably connected to the outer wall of the positioning block 11, the outer wall of the telescopic rod 13 is sleeved with a spring 14 fixedly connected to the outer wall of the positioning block 11, one end of the spring 14 is fixedly connected with a pulling block 15 fixedly connected to one end of the telescopic rod 13, and a clamping groove 16 is provided at the connection between the outer wall of the fixing block 10 and the clamping rod 12.

[0021] Furthermore, two groups of incubators 4, cytotoxicity assay equipment 6, GSH and ROS assay equipment 7 and QCT and RES combined preparation mixed administration equipment 17 are provided. The positions of the two groups of incubators 4, cytotoxicity assay equipment 6, GSH and ROS assay equipment 7 and QCT and RES combined preparation mixed administration equipment 17 are symmetrical about the central axis of the partition 2, which is beneficial to the use of experimental groups and control groups on both sides of the overall equipment 1, so as to play a role of repeated experiments and comparison.

[0022] Furthermore, four groups of blue LEDs 5 are provided, and the positions of the four groups of blue LEDs 5 are distributed around the incubator 4. By providing four groups of blue LEDs 5 distributed around the incubator 4, a blue-rich environment is provided inside the incubator 4.

[0023] Furthermore, the pull-out plate 3 and the connection block 9 are arranged in a one-to-one correspondence, which is beneficial for placing the test equipment one by one for testing.

[0024] Furthermore, the outer wall profiles of the positioning block 11 and the clamping rod 12 are in an arc shape, which is beneficial for effectively squeezing the telescopic rod 13 and the spring 14 through the setting of the outer wall profiles of the positioning block 11 and the clamping rod 12 in an arc shape.

[0025] Furthermore, the inner wall contour of the slot 16 is larger than the outer wall contour of the clamping rod 12. The incubator 4 forms a clamping structure with the device as a whole 1 through the positioning block 11 and the clamping rod 12, which is beneficial for driving the incubator 4 to be clamped and fixed in the device as a whole 1 through the clamping connection of the positioning block 11 and the clamping rod 12, thereby improving the stability of the test equipment in the device as a whole 1.

[0026] Working principle: When using the combined preparation mixed drug delivery device for blue light-induced ocular surface cell inflammation, when conducting drug trials through the mixed drug delivery device, the initial concentration of QCT and RES reagents can be applied to the QCT and RES combined preparation mixed drug delivery device 17 on the left side of the partition 2. The combined preparation reagent mixed drug delivery device will continuously adjust the concentrations of QCT and RES according to the experimental data, and perform quantitative proportioning. Benzalkonium chloride is applied in the mixed drug delivery device on the right side of the partition 2 as a blank control to find the maximum no-effect dose and the minimum effect dose. Repeated experiments are performed to collect data to find the optimal concentration range of the combined preparation of QCT and RES for treating blue light oxidative damage to ocular surface cells. At the same time, in order to improve the stability of the device in the overall device 1, the fixed block 10 can be connected to the clamping rod 12 through the connection of the connecting block 9, and when the connection part between the clamping rod 12 and the fixed block 10 is in an arc shape, the telescopic rod 13 and the spring 14 are squeezed until the clamping rod 12 slides into the inner wall of the clamping slot 16, thereby improving the placement stability between the device and the overall device 1.

[0027] This is how this combined formulation mixed delivery device for blue light-induced ocular surface cell inflammation works.

[0028] The device is intended to make up for the defects of the prior art in the research experimental steps, and is used to find the optimal concentration range of the combined preparation of QCT and RES for treating blue light oxidative damage to ocular surface cells. The embodiments of the utility model are given for the purpose of illustration and description, and are not intended to be exhaustive or to limit the utility model to the disclosed form. Many modifications and changes are obvious to those of ordinary skill in the art. The embodiments are selected and described in order to better illustrate the principles and practical applications of the utility model, and to enable those of ordinary skill in the art to understand the utility model and design various embodiments with various modifications suitable for specific purposes.

Claims

1. A combined preparation mixed drug delivery device for blue light-induced ocular surface cell inflammation, comprising a device as a whole (1), characterized in that: The inner wall of the device as a whole (1) is fixedly connected to a partition (2), the inner wall of the device as a whole (1) is slidably connected to a pull-out plate (3), the outer wall of the pull-out plate (3) is provided with an incubator (4) which is snap-fitted and connected to the inner wall of the device as a whole (1), the interior of the incubator (4) is provided with a blue light-emitting diode (5), the inner wall of the device as a whole (1) is provided with a cytotoxicity measuring device (6) located below the incubator (4), the inner wall of the device as a whole (1) is connected to a GSH and ROS measuring device (7) located below the cytotoxicity measuring device (6), the detection devices of the cytotoxicity measuring device (6) and the GSH and ROS measuring device (7) are both connected to the incubator (4), the interior of the device as a whole (1) is provided with a QCT and RES combined preparation mixed administration device which is located above the incubator (4) and is embedded with the incubator (17), a handle (8) is fixedly connected to the side wall of the device as a whole (1), a connecting block (9) is fixedly connected to the back of the incubator (4), the outer wall of the connecting block (9) is fixedly connected to the fixing block (10), the inner wall of the device as a whole (1) is fixedly connected to a positioning block (11) located on one side of the fixing block (10), the outer wall of the positioning block (11) is slidably connected to a clamping rod (12), the outer wall of the clamping rod (12) is fixedly connected to a telescopic rod (13) slidably connected to the outer wall of the positioning block (11), the outer wall of the clamping rod (12) is fixedly connected to a spring (14) fixedly connected to the outer wall of the positioning block (11), one end of the spring (14) is fixedly connected to a pulling block (15) fixedly connected to one end of the telescopic rod (13), and a clamping groove (16) is provided at the connection portion between the outer wall of the fixing block (10) and the clamping rod (12).

2. A combined preparation mixed drug delivery device for blue light-induced ocular surface cell inflammation according to claim 1, characterized in that: The incubator (4), the cytotoxicity determination device (6), the GSH and ROS determination device (7) and the QCT and RES combined preparation mixed administration device (17) are all provided in two identical groups, and the positions of the two groups of the incubator (4), the cytotoxicity determination device (6), the GSH and ROS determination device (7) and the QCT and RES combined preparation mixed administration device (17) are distributed symmetrically with respect to the central axis of the partition (2).

3. A combined preparation mixed drug delivery device for blue light-induced ocular surface cell inflammation according to claim 1, characterized in that: Four groups of blue light emitting diodes (5) are provided, and the positions of the four groups of blue light emitting diodes (5) are distributed around the incubator (4).

4. A combined preparation mixed drug delivery device for blue light-induced ocular surface cell inflammation according to claim 1, characterized in that: The pull-out plates (3) and the connecting blocks (9) are arranged in a one-to-one correspondence.

5. The combined preparation mixed drug delivery device for blue light-induced ocular surface cell inflammation according to claim 1, characterized in that: The outer wall profiles of the positioning block (11) and the clamping rod (12) are in an arc shape.

6. The combined preparation mixed drug delivery device for blue light-induced ocular surface cell inflammation according to claim 1, characterized in that: The inner wall profile of the clamping groove (16) is larger than the outer wall profile of the clamping rod (12).

Images